• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Johnson & Johnson Vision wins Fast Company award for drug-eluting contact lens

May 4, 2022 By Sean Whooley

Johnson & Johnson Vision drug eluting contact lens acuvue Theravision_FDA Revised Carton
[Image from Johnson & Johnson Vision]
Johnson & Johnson Vision announced today that it was named a winner of Fast Company’s 2022 World Changing Ideas Awards.

The eye health business arm of Johnson & Johnson (NYSE: JNJ) received the award in the “Wellness” category for its Acuvue Theravision with ketotifen (etafilcon A drug-eluting contact lens with ketotifen). The drug-eluting contact, which provides a new wearing experience for contact lens wearers who have allergic eye itch for up to 12 hours without the need for allergy drops while also providing vision correction, received FDA approval in March.

Health Canada approved the drug-eluting contact lens in April 2021, just one month after the product received regulatory approval in Japan. Director of Clinical Science Dr. Brian Pall told Drug Delivery Business News in March that the offering represents the world’s first drug-eluting contact lens.

Fast Company also chose Acuvue Theravision with ketotifen for an honorable mention in its “Health” and “Enduring Impact:15+ Years in Business” categories, according to a news release. Johnson & Johnson was recognized as a winner out of a pool of nearly 3,000 entries across health, wellness, technology, transportation, education and more.

“At Johnson & Johnson Vision, we are guided by an incredible sense of purpose and a bold ambition to redefine healthy sight for life,” Johnson & Johnson Vision Company Group Chair Peter Menziuso said in the release. “Congratulations to all our teams, patients, and eye care professionals who have been instrumental in introducing this entirely new category of contact lens. We are constantly pushing the boundaries of what’s possible to improve eye health, and the recognition of Acuvue Theravision with ketotifen as a World Changing Idea is both an honor and a summons for us to continue anticipating and creating solutions to help more people see better, connect better, live better.”

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Optical/Ophthalmic Tagged With: Johnson & Johnson, Johnson & Johnson Vision

IN CASE YOU MISSED IT

  • Abbott could pave new roads in diabetes management with dual sensor on the horizon
  • Tandem Diabetes Care pairs t:slim X2 pump with Abbott FreeStyle Libre 3 Plus in U.S.
  • Ypsomed, CamDiab to integrate Abbott dual glucose-ketone sensor into automated insulin delivery system
  • PharmaSens, SiBionics collab on all-in-one insulin patch pump
  • Beta Bionics to pair iLet automated insulin delivery system with Abbott’s dual glucose-ketone sensor

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS